Cencora (COR) just released its second quarter results, with sales of US$78.4b and net income of US$1.6b, drawing fresh attention to how the stock reflects its healthcare distribution and specialty pharma exposure.

The earnings release has arrived alongside a sharp reset in sentiment, with the share price at US$252.74 after a 1-day share price return decline of 17.38% and a 90-day share price return decline of 28.23%. However, the 5-year total shareholder return of 121.89% points to investors who stayed the course seeing a very different experience over the longer run.

If you are weighing Cencora's recent earnings against other healthcare opportunities, this can be a useful moment to scan the market using a focused list of 32 healthcare AI stocks

So with Cencora now trading at US$252.74 alongside sizeable earnings and an apparent discount to some valuation estimates, are you looking at a genuine opportunity, or is the market already pricing in the company’s future growth?

Most Popular Narrative: 37.3% Undervalued

At a last close of $252.74 against a narrative fair value of $402.92, Cencora is framed as meaningfully undervalued, with that gap tied closely to how future growth, margins, and capital allocation could play out.

Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act, improving supply chain efficiency and transparency, which should drive higher net margins and operating income over time.

Curious what sits behind a fair value that is far above today’s price? The narrative leans on compounding revenue, rising profitability, and a richer earnings multiple to justify that target, all quantified year by year.

Result: Fair Value of $402.92 (UNDERVALUED)

However, that upside story still leans on assumptions, and pressures from lower margin generics and ongoing regulatory scrutiny could quickly weaken the bullish case.

Another Way to Look at Cencora’s Value

The DCF view is generous, with Cencora trading at 58.3% below one estimate of fair value based on future cash flows at $606.79. Yet the market is already pricing the stock on a P/E of 30.3x, slightly above a fair ratio of 30.2x and above the US Healthcare average of 25.2x. This points to less obvious room for error if earnings or sentiment slip. So is this a genuine disconnect or a sign that the cash flow model is leaning too hard on optimistic assumptions?

Next Steps

With sentiment clearly mixed, this is the moment to look through the numbers, weigh both risk and reward, and judge for yourself using the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop with one healthcare stock when you can line up a watchlist of ideas that fit your goals and risk comfort, starting right now.

• Target potential mispricings by scanning a curated set of quality candidates through the 44 high quality undervalued stocks
• Strengthen your income focus by hunting for reliable yield opportunities using the 12 dividend fortresses
• Prioritize resilience by zeroing in on companies flagged in the 74 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.